Auspex Pharmaceuticals Announces Data From Interim Analysis Of ARC-HD Switch Trial Demonstrating Clinical Activity Of SD-809

Published: Jun 24, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LA JOLLA, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced results from a pre-specified interim subgroup analysis of the ongoing open-label ARC-HD Switch study in which the clinical experience of switching subjects' treatment from tetrabenazine to SD-809 was evaluated.

Help employers find you! Check out all the jobs and post your resume.

Back to news